Abbott Laboratories shares plunged 5.6% on Thursday to close at $95.85, as investors hammered the medical device giant following disappointing guidance issued after its Exact Sciences acquisition. The stock tumbled on volume of 12.3M shares, wiping significant value off the company’s $166.6B market cap in a single session.
The selloff centered on post-acquisition guidance that fell short of investor expectations. Abbott issued updated forecasts following its acquisition of Exact Sciences, a deal that appears to have raised more questions than answers about near-term profitability and integration costs. The market’s reaction was swift and unforgiving, with the stock posting one of its worst single-day performances in recent memory as traders digested the implications of the company’s revised outlook.
The guidance disappointment compounds uncertainty around Abbott’s strategic direction in the medical device space. While acquisitions can create long-term value through expanded product portfolios and market reach, investors are clearly skeptical about the immediate financial impact of the Exact Sciences deal. The sharp decline suggests concerns about whether Abbott paid too much, whether integration will be smoother than expected, or whether the combined entity’s revenue and margin profile will meet the bar Wall Street had set.
Trading activity Thursday showed genuine distribution, with volume confirming the downside move. The 5.6% drop represents a meaningful reset in valuation, though without additional context on where the stock sits relative to its recent range, it’s unclear whether this creates a buying opportunity or signals further pain ahead. Medical device stocks have faced headwinds from reimbursement pressures and competitive dynamics, and Abbott’s acquisition-driven strategy now faces investor scrutiny.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.